TYG Solutions

TYG Solutions is a clinical-stage biotechnology company specializing in the development of active immunotherapies for gastrointestinal and other solid tumors. The company's core technology, the Synthetic Target Mimetic (S-T-M) platform, enables the design of vaccines that induce high-affinity neutralizing antibodies against self-antigens like gastrin. Its lead candidate, TYG100, targets the gastrin-CCK2R signaling pathway, which is a known driver of tumor growth and chemoresistance in pancreatic and gastric cancers. By leveraging this targeted approach, TYG Solutions aims to provide more effective and less toxic treatment options for patients with difficult-to-treat malignancies.